Incidence and severity of DS event by study and type of AML (ND or R/R; AML safety population). ND patients received no prior treatment for AML. No patients experienced >3 DS events. There is no grade 1 category per site guidelines for DS. DS events included possible and probable cases of DS. Number and percentage of patients in each group shown as n (%). Patients were treated with enasidenib (100 mg or 200 mg per day) in combination with azacitidine 75 mg/m² per day. Patients were treated with enasidenib (100 mg once daily) in combination with cytarabine (200 mg/m² per day for 7 days) and either daunorubicin (60 mg/m² per day for 3 days) or idarubicin (12 mg/m² per day for 3 days). AML, acute myeloid leukemia; DS, differentiation syndrome; ND, newly diagnosed; R/R, relapsed or refractory.